Skip to main content

Research Repository

Advanced Search

Promising investigational drug candidates in phase I and phase II clinical trials for mesothelioma

Guazzelli, A; Bakker, EY; Tian, K; Demonacos, C; Krstic- Demonacos, M; Mutti, L

Promising investigational drug candidates in phase I and phase II clinical trials for mesothelioma Thumbnail


Authors

A Guazzelli

EY Bakker

K Tian

C Demonacos

L Mutti



Abstract

Introduction: Malignant mesothelioma is a rare and lethal malignancy primarily affecting the pleura and peritoneum. Mesothelioma incidence is expected to increase worldwide and current treatments remain ineffective, leading to poor prognosis. Within this article potential targets to improve the quality of life of the patients and assessment of further avenues for research are discussed.

Areas covered: This review highlights emerging therapies currently under investigation for malignant mesothelioma with a specific focus on phase I and phase II clinical trials. Three main areas are discussed: immunotherapy (immune checkpoint blockade and cancer vaccines, among others), multitargeted therapy (such as targeting pro-angiogenic genes) and gene therapy (such as suicide gene therapy). For each, clinical trials are described to detail the current or past investigations at phase I and II.

Expert opinion: The approach of applying existing treatments from other cancers does not show significant benefit, with the most promising outcome being an increase in survival of 2.7 months following combination of chemotherapy with bevacizumab. It is our opinion that the hypoxic microenvironment, the role of the stroma, and the metabolic status of mesothelioma should all be assessed and characterised to aid in the development of new treatments to improve patient outcomes.

Citation

Guazzelli, A., Bakker, E., Tian, K., Demonacos, C., Krstic- Demonacos, M., & Mutti, L. (2017). Promising investigational drug candidates in phase I and phase II clinical trials for mesothelioma. Expert Opinion on Investigational Drugs, 26(8), 933-944. https://doi.org/10.1080/13543784.2017.1351545

Journal Article Type Article
Acceptance Date Jul 3, 2017
Online Publication Date Jul 12, 2017
Publication Date Jul 12, 2017
Deposit Date Jul 14, 2017
Publicly Available Date Jul 12, 2018
Journal Expert Opinion on Investigational Drugs
Print ISSN 1354-3784
Electronic ISSN 1744-7658
Publisher Taylor and Francis
Volume 26
Issue 8
Pages 933-944
DOI https://doi.org/10.1080/13543784.2017.1351545
Publisher URL http://dx.doi.org/10.1080/13543784.2017.1351545
Related Public URLs http://www.tandfonline.com/toc/ieid20/current

Files

Preprint Version Promising investigational drug candidates in phase I and phase II clinical trials for mesothelioma PDF.pdf (858 Kb)
PDF






You might also like



Downloadable Citations